A recent analysis showed that aftercare strategies for soft-tissue sarcoma are misguided and are in need of time- and risk-adapted methods.

Conferences

Health-related quality of life (HRQoL) and its impact on disease progression should be a critical consideration when selecting treatment for patients with soft-tissue sarcoma (STS), according to a study presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL (June 3-7, 2016).

Read More

News

Data from the National Cancer Database, which is heavily dependent on institutional reporting, could be misleading about the burden of sarcomas in the United States, according to a presentation at the Connective Tissue Oncology Society 2017 Annual Meeting (November 8-11, 2017; Maui, Hawaii).

Read More

A recent analysis examined whether changes to the latest American Joint Committee on Cancer (AJCC) cancer staging manual on retroperitoneal sarcoma have improved staging system performance, published in Annals of Surgical Oncology (online October 20, 2017; doi:10.1245/s1043).

Read More

Pediatric patients with head and neck sarcoma can be treated with proton beam therapy and experience similar outcomes with less impact on quality of life (QoL) compared with standard photon radiation, according to research published in Pediatric Blood & Cancer (online October 23, 2017; doi:10.1002/pbc.26858).

Read More

A recent study demonstrated meaningful clinical activity with limited toxicity in patients with soft-tissue and bone sarcoma after treatment with an immuno-agent.

Read More

Quiz

In the highly active antiretroviral therapy era, which secondary malignancy to Kaposi sarcoma has emerged as a new risk for patients?

In the highly active antiretroviral therapy era, which secondary malignancy to Kaposi sarcoma has emerged as a new risk for patients?

-----

A. Chronic myeloid leukemia

B. Chronic lymphocytic leukemia

C. Acute lymphocytic leukemia

D. Diffuse large B-cell lymphoma

-----

Read More

According to a recent study published in The LANCET Oncology, which treatment option is considered and should remain the standard of care for soft-tissue sarcoma?

-----

A. Gemcitabine

B. Doxorubicin

C. Eribulin 

D. Gemcitabine plus doxorubicin 

-----

Read More

According to a recent study published in The LANCET Oncology, which treatment option is considered and should remain the standard of care for soft-tissue sarcoma?

-----

A. Gemcitabine

B. Doxorubicin

C. Eribulin 

D. Gemcitabine plus doxorubicin 

-----

Read More

Research in Review

The best potential strategy involving tyrosine kinase inhibitors (TKIs) for the treatment of gastrointestinal stromal tumors (GISTs) has been identified, according to new research published in Clinical Drug Investigation.

Read More

Kaposi Sarcoma (KS) skin lesions are more likely to respond to local external beam radiotherapy than repeat radiotherapy, according to a study conducted by members of the Department of Radiation Oncology, University of Toronto (ON, Canada), and published in Annals of Palliative Medicine.
-----
Related Content

Read More

Tivozanib was well-tolerated and showed promising antitumor activity in patients with soft tissue sarcoma overexpressing vascular endothelial growth factors (VEGF), supporting efforts for further research, according to a study published in Annals of Oncology.

-----

Related Content

Read More

Neoadjuvant chemotherapy with epirubicin plus ifosfamide improves outcomes in patients with soft tissue sarcoma of the trunk or extremities who are at high-risk of recurrence, according to a study presented at the European Society for Medical Oncology 2016 Congress in Copenhagen, Denmark (October 7-11, 2016).

Read More

Subscribe to Sarcoma